By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
The Manual for Electric Vehicles that will be hot merchants in 2023 - 2Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- 3Israel launches new wave of attacks against Hezbollah in Beirut
- 4RFK Jr. says he's following 'gold standard' science. Here's what to know
- 5This is Countdown, CNN’s newsletter covering NASA’s first time sending humans to deep space in over 50 years
- 'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- Sound Maturing: Wellbeing Tips for Each Life Stage
- ByHeart baby formula from all lots may be contaminated with botulism bacteria, tests show
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
- A photographer's journey to capture a blood moon rising over the South China Sea. 'It was an incredible moment'
- IDF strikes terror infrastructure across Iran, attack reported on Kashan airport
- Find Serenity: 10 Stunning Setting up camp Areas
- Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- More loons are filling Maine's lakes with their ghostlike calls
